首页> 外文OA文献 >GA101 P329GLALA, a variant of obinutuzumab with abolished ADCC, ADCP and CDC function but retained cell death induction, is as efficient as rituximab in B-cell depletion and antitumor activity

【2h】

GA101 P329GLALA, a variant of obinutuzumab with abolished ADCC, ADCP and CDC function but retained cell death induction, is as efficient as rituximab in B-cell depletion and antitumor activity

机译：GA101 P329Glala是由废除ADCC，ADCP和CDC功能但保留细胞死亡诱导的obInutuzumab的变体，与B细胞耗尽和抗肿瘤活性中的Rituximab有效

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Sylvia Herter; Frank Herting; Gunter Muth; Erwin van Puijenbroek; Tilman Schlothauer; Claudia Ferrara; Kevin Brady; Sabine Lang; Marina Bacac; Ekkehard Mössner; Pablo Umana; Christian Klein;
展开▼
作者单位

展开▼
年度 2017
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Obinutuzumab (GA101) is highly effective against chronic lymphocytic leukemia cells in ex vivo B-cell depletion irrespective of high-risk prognostic markers [J] . L Ysebaert, E Laprévotte, C Klein, Blood cancer journal. . 2015,第11期

机译：奥比妥珠单抗（GA101）对体内i细胞B细胞耗竭的慢性淋巴细胞性白血病非常有效，而与高风险预后标志物无关
2. Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20(+) Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study [J] . Sehn Laurie H., Goy Andre, Offner Fritz C., Journal of Clinical Oncology . 2015,第30期

机译：II期随机试验比较Obinutuzumab（GA101）与Rituximab在复发性CD20（+）惰性B细胞非霍奇金淋巴瘤患者中的作用：GAUSS研究的最终分析
3. Role for ZAP-70 Signaling in the Differential Effector Functions of Rituximab and Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia B Cells [J] . Skopelja-Gardner Sladjana, Jones Jonathan D., Hamilton B. JoNell, The Journal of Immunology: Official Journal of the American Association of Immunologists . 2017,第4期

机译：ZAP-70在慢性淋巴细胞白血病B细胞中Rituximab和ObInutuzumab（Ga101）的差动效应函数中的作用
4. Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma [C] . Bohua Li, Hao Wang, Yajun Guo, International conference of molecular simulations and applied informatics technologies . 2012

机译：具有抗利妥昔单抗的B细胞淋巴瘤的有效抗肿瘤活性的利妥昔单抗变体的表征
5. GA101 P329GLALA a variant of obinutuzumab with abolished ADCC ADCP and CDC function but retained cell death induction is as efficient as rituximab in B-cell depletion and antitumor activity [O] . Sylvia Herter, Frank Herting, Gunter Muth, 2018

机译：GA101 P329GLALA是obinutuzumab的变体具有废除ADCCADCP和CDC功能但保留了细胞死亡诱导作用在B细胞耗竭和抗肿瘤活性方面与利妥昔单抗一样有效
6. Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20(+) Indolent B-Cell Non-Hodgkin Lymphoma:Final Analysis of the GAUSS Study [O] . Sehn, L. H., Goy, A., Offner, F. C., 2015

机译：比较奥比妥珠单抗（GA101）与利妥昔单抗治疗CD20（+）惰性B细胞非霍奇金淋巴瘤复发患者的随机II期试验：GAUSS研究的最终分析

GA101 P329GLALA, a variant of obinutuzumab with abolished ADCC, ADCP and CDC function but retained cell death induction, is as efficient as rituximab in B-cell depletion and antitumor activity

著录项

相似文献

相关主题

期刊订阅